Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144377 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2541546 in Women With Low Bone Mineral Density
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT01144377 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 154 participants.
The verdict
NCT01144377, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The primary objectives of this study include evaluating the dose response of LY2541546 using bone mineral density (BMD) change from baseline as compared to placebo and evaluating the overall safety and tolerability of LY2541546 following multiple subcutaneous administrations in postmenopausal (PMP) women with low BMD. Following the last dose of study drug, participants will be able to participate in a 12 month extension to collect additional safety and efficacy data (no further treatment will be administered during this extension).
Interventions
- DRUG Placebo
- DRUG LY2541546
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144377
The ClinicalTrials.gov registry entry for NCT01144377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01144377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144377 about?
NCT01144377 is a clinical study titled "A Study of LY2541546 in Women With Low Bone Mineral Density". The primary objectives of this study include evaluating the dose response of LY2541546 using bone mineral density (BMD) change from baseline as compared to placebo and evaluating the overall safety and tolerability of LY2541546 following multiple subcutaneous administrations in postmenopausal (PMP) ...
What is the current status of trial NCT01144377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2010-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01144377?
The interventions under investigation include: Placebo (DRUG), LY2541546 (DRUG).
Who is sponsoring clinical trial NCT01144377?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.